Extended Data Fig. 5: Kaplan–Meier curve for the time (in months) from randomization to the first primary endpoint, excluding PAD from the composite primary outcome definition. | Nature Medicine

Extended Data Fig. 5: Kaplan–Meier curve for the time (in months) from randomization to the first primary endpoint, excluding PAD from the composite primary outcome definition.

From: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial

Extended Data Fig. 5: Kaplan–Meier curve for the time (in months) from randomization to the first primary endpoint, excluding PAD from the composite primary outcome definition.The alternative text for this image may have been generated using AI.

Spironolactone versus usual care (two-sided test), excluding PAD from the composite primary outcome. P-value level of significance = 0.05. PAD: peripheral arterial disease.

Back to article page